Skip to main content

Advertisement

Table 1 Summary of the 50% inhibition concentration (IC50) of evofosfamide in nasopharyngeal carcinoma cell lines

From: Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo

Cell line IC50 of evofosfamide HCR (N/H)
N (μmol/L) H (μmol/L)
CNE-2 77.62 ± 8.86 8.33 ± 0.75** 9
HONE-1 87.18 ± 19.19 7.62 ± 0.67** 11
HNE-1 103.97 ± 12.91 0.31 ± 0.07** 335
  1. N normoxia, H hypoxia, HCR hypoxia cytotoxicity ratio
  2. **P < 0.01